Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW
|
|
- Annabel Carr
- 8 years ago
- Views:
Transcription
1 Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW
2 Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia Disturbance in executive functioning Substantial impairment in social or occupational functioning Deficits that do not occur exclusively during the course of delirium
3 Subtypes of Dementia Alzheimer s Disease Vascular Dementia Parkinson s Disease Dementia with Lewy Bodies Frontotemporal Dementias : e.g. Pick s disease Substance induced persistent Dementia Dementia due to HIV Disease
4 Alzheimer s disease
5 Alzheimer s Disease : Clinical The most common form of dementia, accounting for 50 to 56% of cases Slow onset Short-term memory impairment Relative preservation of remote memory Gradual deterioration of cognitive capacities
6 Alzheimer s Disease: Risk Factors Advanced Age Family History of AD Parkinson s Disease Down s Syndrome Genetic Factors History of Head Injury
7 Alzheimer s disease Pathogenesis
8 Pathogenesis : Alzheimer's disease caused by accumulation of abnormally folded beta amyloid and tau proteins in the brain triggering neuron degeneration. Cerebral plaques laden with β-amyloid peptide (Aβ) and dystrophic neurites in neocortical terminal fields as well as prominent neurofibrillary tangles in medial temporal-lobe structures are important pathological features of Alzheimer's disease. NEJM ; Volume 362: January 28, 2010
9 Beta-amyloid is a fragment of amyloid precursor protein (APP), a transmembrane protein In AD, an unknown process causes APP to be divided into smaller fragments by enzymes through proteolysis One of these fragments gives rise to fibrils of beta-amyloid, which form clumps that deposit outside neurons in dense formations known as senile plaques Amyloid fibrils from the viewpoint of protein folding. Cell. Mol. Life Sci. 61 (5):
10 Tau protein stabilizes the microtubules when phosphorylated, and therefore called a microtubule-associated protein In AD, tau becoming hyperphosphorylated then begins to pair with other threads, creating neurofibrillary tangles Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739 (2-3):
11 N Engl J Med 2004;351:56-67.
12 Neurotransmitter in AD : Acetylcholine Deficiency of cholinergic projections has been linked to the build-up of Aβ and tau. Aβ binds to nicotinic acetylcholine receptors, impairing the release of acetylcholine and maintenance of long-term potentiation. The level of muscarinic acetylcholine receptors is reduced in the brains of patients with Alzheimer's disease. Glutamate Chronic state of excitatory amino acid (glutaminergic) receptor activation is thought to aggravate neuronal damage in late-stage Alzheimer's disease NEJM ; Volume 362: January 28, 2010
13 Acetylcholine Pathways : Two major cholinergic projections within CNS 1. Ascending reticular activating system - Sleep-wake cycles 2. Cortical structures: neocortex, hippocampus and amygdala - Learning and memory function
14 Cholinergic deficit in AD : Progressive decrease in avaliable Ach Impairment in ADL, behavior and cognition
15 Glutamate pathways : Glutamate is the fast excitatory neurotransmitter in regions associated with cognition and memory. Cortical and subcortical structures that contained glutaminergic receptors are structurally damage in AD. Glutamate acts as an excitotoxin causing neuronal death when excessive levels are chronically released.
16 Excitatory amino acids as a final common pathway in neurologic disorders. N Engl J Med 330: , 1994 Pathways for excitotoxicity in AD : Energy deficiency Decrease in membrane potential Decrease glutamate uptake Increase glutamate release Increase glutamate levels NMDA receptor activation Increased Ca2+ influx Excitotoxicity
17 N-Methyl-D-Aspartate Receptors : Excessive activation of NMDA receptors can lead to massive Ca2+ influx and trigger irreversible process leading to cell death.
18 Cholinesterase inhibitors and memantine use for Alzheimer s disease Effectiveness and adverse events
19 Disease Modifying Agents use in dementia N Engl J Med 2004;351:56-67.
20 Alzheimer Disease Assessment Scale Cognitive Subscale (ADAS-cog) 11-Item Score range Memory and new learning 0-35 Word recall (mean number of words not recalled) 0-10 Orientation 0-8 (one point for each incorrect response) Word recognition 0-12 (mean number of incorrect responses) Remembering test instructions 0-5 Language 0-25 Commands 0-5 Spoken language ability 0-5 Naming objects/fingers 0-5 Word-finding difficulty 0-5 Comprehension 0-5 Praxis 0-10 Constructional praxis 0-5 Ideational praxis 0-5 Total 0-70 Increasing scores indicate worsening cognitive function. Rosen WG, et al. Am J Psychiatry. 1984;141:
21 Clinician s Interview Based Impression of Change plus Caregiver Input CIBIC- PLUS Global ratings of patient s clinical condition Rated by the clinician, by interviewing both patients & informant Clinical Impression of Change : Total 7 points 1 = Very Much Improved 2 = Much Improved 3 = Minimally Improved 4 = No change 5 = Minimal worsening 6 = Much worsening 7 = Very much worsening
22 Cholinesterase inhibitors Cholinesterase inhibitors are approved by FDA for the treatment of mild to moderate Alzheimers disease. Clinical trials have shown changes on ADAS-Cog of 2.5 to 3.5 points (range of scores, 0 to 70) and differences on the CIBIC-Plus of 0.3 to 0.5 (range of scores, 1 to 7) in patients receiving the drug as compared with patients receiving placebo. Optimal duration of treatment is uncertain => duration of most blinded trials has been 6 months N Engl J Med 2004;351:56-67.
23 Cholinesterase inhibitors Side effects reported in clinical trials included Nausea & vomiting Diarrhea Weight loss Insomnia Abnormal dreams Muscle cramps Bradycardia Syncope Fatigue N Engl J Med 2004;351:56-67.
24 Donepezil : Effectiveness & Adverse effects Ann Intern Med. 2008;148:
25 Donepezil : Adverse effects Rates of withdrawal due to adverse events ranged from 0%-57% in treatment groups and 0%-20% in placebo groups. However, no serious harms were attributed to donepezil in any study. Ann Intern Med. 2008;148:
26 Galantamine : Effectiveness & Adverse effects Ann Intern Med. 2008;148:
27 Galantamine : Adverse effect Rates of withdrawal due to adverse events ranged from 4% to 17% for placebo and 8% to 54% for active treatment. No important differences emerged in the rates of serious adverse events between the placebo and galantamine. Ann Intern Med. 2008;148:
28 Rivastigmine : Effectiveness & Adverse effects Ann Intern Med. 2008;148:
29 Rivastigmine : Adverse effects Rates of withdrawal due to adverse events ranged from 0% to 11% in the placebo groups and from 12% to 29% in the treatment groups. Frequency of severe adverse events did not differ between the treatment and placebo. Ann Intern Med. 2008;148:
30 Memantine : N-methyl-d-aspartate antagonist Approved by FDA for the treatment of moderate to severe Alzheimers disease In patients with moderate to severe Alzheimers disease showed the superiority of memantine over placebo as indicated by both the Activities of Daily Living Inventory and the Severe Impairment Battery No clinically differences between patients in the memantine and placebo groups in terms of adverse events N Engl J Med 2004;351:56-67.
31 Memantine : Effectiveness Ann Intern Med. 2008;148:
32 Memantine : Adverse events Adverse events included GI symptom, dizziness, headache No harms reported for memantine was statistically significant Patients withdrawing because of any adverse events varied from 5%to17% in the placebo groups and 8%to13% in the treatment groups Ann Intern Med. 2008;148:
33 Effect size of drug use in Alzheimer s disease (all severity) Drug Outcome of benefit Outcome of harm (Adverse events) ADAS-cog CIBIC-plus Significant AE Serious AE (WMD) (RR) Relative risk Donepezil Anorexia RR 3.21 Galantamine Anorexia RR 3.41 Rivastigmine Vomiting RR 6.06 Memantine NA 1.25 No statistically significant AE No No No No Ann Intern Med. 2008;148:
34 Conclusion For Alzheimer disease, cholinesterase inhibitors and memantine can improve symptoms, primarily in domains of cognition and global function. Clinically important differences were not consistently evaluated or demonstrated in these 2 domains for all drugs. Direct comparisons among these drugs are limited and do not suggest important differences. Adverse events of cholinesterase inhibitors are primarily associated with GI problems Ann Intern Med. 2008;148:
35 Thank you for your attention
36 Vascular dementia
37 Vascular Dementia : Vascular Dementia makes up 15-25% of all dementia cases. Risk factor - Advanced Age - Stroke - Smoking - Obesity - Alcoholism - Hypertension - Diabetes
38 Vascular Dementia : Diagnosis
39 Vascular Dementia : Disruption of cholinergic pathways contributes to the pathophysiology of vascular dementia has led to clinical trials of Cholinesterase inhibitors in treatment of vascular dementia. Clinical trials of memantine suggest benefits in vascular dementia possibly due to its effect in reducing glutamatergic neurotoxicity. In vascular dementia, Donepezil & Memantine showed statistically significant improvement in cognitive function. Lancet Neurol 2007; 6:
40 Donepezil : Ann Intern Med. 2008;148:
41 Memantine : Effectiveness Ann Intern Med. 2008;148:
Alzheimer Disease (AD)
1 Alzheimer Disease (AD) 2 Alzheimer's disease is a progressive degenerative disease that attacks the brain and results in impaired memory, thinking and behavior. It was first described by Dr. Alois Alzheimer
More informationMCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease
MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease Outline of Today s Lecture Why is Alzheimer s disease a problem? What is Alzheimer s Disease? What causes Alzheimer s disease? How can
More informationObjectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment
Dementia David Lam, MD, FRCPC, Psychiatry Assistant Clinical Professor Department of Psychiatry and Behavioural Neurosciences McMaster University Hamilton, Ontario Objectives Aging and Forgetfulness Define
More informationCommon causes of dementia
Common causes of dementia Alzheimer s disease vascular (multi-infarct etc.) dementia dementia of Parkinsonism Huntington s disease Pick s disease Creutzfeldt-Jacob disease etc. DEGENERATIVE DEMENTIA Pick
More informationPrimary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate
More informationDementias have become a major public health concern. Clinical Guidelines
Annals of Internal Medicine Clinical Guidelines Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline Parminder Raina, PhD; Pasqualina
More informationNormal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006
Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006 Alzheimer Disease is a form of dementia that affects 5% of men and
More informationPrimary Endpoints in Alzheimer s Dementia
Primary Endpoints in Alzheimer s Dementia Dr. Karl Broich Federal Institute for Drugs and Medical Devices (BfArM) Kurt-Georg-Kiesinger-Allee 38, D-53175 Bonn Germany Critique on Regulatory Decisions in
More information2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease
2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease Dylan Wint, M.D. ALZHEIMER DISEASE Dylan Wint, M.D. Lou Ruvo Center for Brain Health DEFINITIONS Cognitive related to thinking,
More informationLong Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)
1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s
More informationUpdate on Treatment of the Dementias
Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label
More informationEveryone has mild memory lapses from time to time. You go
Coping With Memory Loss Everyone has mild memory lapses from time to time. You go from the kitchen to the bedroom to get something, only to find yourself wondering what you needed. You can t find your
More informationMental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca
Mental health issues in the elderly January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca Cognitive Disorders Outline Dementia (294.xx) Dementia of the Alzheimer's Type (early and late
More informationA 5-HT 6 antagonist in advanced development for the treatment of mild and moderate Alzheimer s disease: idalopirdine (Lu AE58054)
A 5-HT 6 antagonist in advanced development for the treatment of mild and moderate Alzheimer s disease: idalopirdine (Lu AE58054) producti Congrès National des unités de soins, d'évaluation et de prise
More informationAlzheimer's: The Latest Assessment and Treatment Strategies
Questions from chapter 1 Alzheimer's: The Latest Assessment and Treatment Strategies 1) What is a loss of cognitive and intellectual powers without changes in consciousness. a) dementia b) delusions c)
More informationU.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007, August 2009) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a review of NICE
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN 2319-2003 Online ISSN 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.5455/2319-2003.ijbcp20150415 Research Article A prospective open-label randomized comparative
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationAlzheimer s disease. What is Alzheimer s disease?
Alzheimer s disease What is Alzheimer s disease? What we know about dementia and Alzheimer s disease Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible
More informationCHAPTER- 6. Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats. 1. Introduction. 2. Methods
CHAPTER- 6 Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats 1. Introduction Neurodegenerative disorders, such as AD are often characterized by the degeneration of the
More informationStaging and Treatment of Dementia
Staging and Treatment of Dementia Ami Hall DO 10/25/14 1 Objectives What are the two most common types of dementias seen in a primary care office How are they staged What treatments are available Definition
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationDonepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease
IS 11 October 2011 Information sheet Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease Introduction... 1 How does Aricept work?... 1 Who might benefit from Aricept?... 2 What effect
More informationPharmacotherapy of BPSD. Pharmacological interventions. Anti-dementia drugs. Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence
Pharmacotherapy of BPSD Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence Pharmacological interventions Reducing medication errors. Reducing potentially inappropriate medication prescription.
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More informationCRITERIA FOR AD DEMENTIA June 11, 2010
CRITERIA F AD DEMENTIA June 11, 2010 Alzheimer s Disease Dementia Workgroup Guy McKhann, Johns Hopkins University (Chair) Bradley Hyman, Massachusetts General Hospital Clifford Jack, Mayo Clinic Rochester
More informationDonepezil, galantamine, rivastigmine and memantine for Alzheimer s disease
Understanding NICE guidance Information for people who use NHS services Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease NICE technology appraisal guidance advises on when and
More informationNHS ONEL and NELFT Shared Care Guidelines. Management of medications for Alzheimer s disease. Patient Name : Date of Birth: NHS No:
NHS ONEL and NELFT Shared Care Guidelines Management of medications for Alzheimer s disease DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name
More informationAlzheimer Disease Pharmacologic Treatment and Treatment Research Lon S. Schneider, MD, MS
Review Article Alzheimer Disease Pharmacologic Treatment and Treatment Research Lon S. Schneider, MD, MS ABSTRACT Purpose of Review: This article reviews marketed pharmacologic treatments for Alzheimer
More informationGuidelines for Dementia Syndrome
Guidelines for Dementia Syndrome Dementia is the chronic acquired decline in memory and at least one other cognitive function (e.g. language, visual-spatial, executive) sufficient to offset daily life.
More informationbasics of alzheimer s disease What it is and what you can do
basics of alzheimer s disease What it is and what you can do What is Alzheimer s disease? Alzheimer s (AHLZ-high-merz) is a disease of the brain that causes problems with memory, thinking and behavior.
More informationDisorders Considered. A Brief Synopsis of Select Neurological Disorders. Neurological and Psychiatric Symptoms. Neurological Basis
Disorders Considered A Brief Synopsis of Select Neurological Disorders Four neurological disorders are examined to illustrate pathological conditions that can develop related to course material Myasthenia
More informationShared Care Protocol for the Prescription of Memantine for Alzheimer s disease
Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease 1. REFERRAL CRITERIA Patients of any age that are suspected to be suffering from moderate to severe Alzheimer s disease will
More informationwww.bpac.org.nz keyword: donepezil The pharmacological management of Alzheimer s disease: The place of donepezil 28 BPJ Issue 30
www.bpac.org.nz keyword: donepezil The pharmacological management of Alzheimer s disease: The place of donepezil 28 BPJ Issue 30 Donepezil to be funded for the treatment of Alzheimer s disease As the world
More informationBiomarkers for Alzheimer's Disease in Down Syndrome
Biomarkers for Alzheimer's Disease in Down Syndrome Brad Christian, Ph.D. Waisman Laboratory for Brain Imaging Outline Rationale for Studying AD in Down Syndrome Background of Alzheimer s Disease Biomarkers
More informationAlzheimer s and Depression: What is the Connection?
Alzheimer s and Depression: What is the Connection? Ladson Hinton MD Professor and Director of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Director, Education Core, Alzheimer
More informationDementia. Your medicine. Information for you. Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa
Dementia Your medicine Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other formats
More informationCognitive impairment (CI) in Multiple Sclerosis
Multiple Sclerosis and Mild Cognitive Impairment What are the cognitive impairments in MS and why are the terms dementia and Mild Cognitive Impairment (MCI) rarely used? By Ronald Devere, MD Cognitive
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationMemantine (Ebixa) Drug treatment for Alzheimer s disease
IS 20 October 2011 Information sheet Memantine (Ebixa) Drug treatment for Alzheimer s disease Introduction... 1 How does Ebixa work?... 1 Who might benefit?... 2 What effect might Ebixa have?... 2 How
More informationUPDATES TO NEUROCOGNITIVE DISORDERS IN DSM-5 and DSM-5 DESK REFERENCE UPDATED 10-18-13
UPDATES TO NEUROCOGNITIVE DISORDERS IN DSM-5 and DSM-5 DESK REFERENCE UPDATED 10-18-13 SUMMARY: These coding changes ensure that insurance reimbursement can be obtained when the specifier With behavioral
More informationAlzheimer s Drugs. Oregon Health Resources Commission. Subcommittee Report. Update #1 October 2006
Oregon Health Resources Commission Alzheimer s Drugs Subcommittee Report Update #1 October 2006 Produced by: Health Resources Commission Kathleen Weaver, MD, Director Office for Health Policy & Research
More informationDisclosures. Case: Ms. K. Case: Ms. K. Dementia: Considering When to Start, Stop, and Continue Medications 4/23/15. * Nothing to disclose
Dementia: Considering When to Start, Stop, and Continue Medications * Nothing to disclose Disclosures Lianne Hirano, MD UW Division of Gerontology & Geriatric Medicine 4/23/15 Current Concepts in Drug
More informationCEN Outreach Neurological Disorders
CEN Outreach Neurological Disorders Migraine, Mul,ple Sclerosis, Alzheimer s Disease Migraine Migraine is the most common neurological disorder in the developed world Almost 1 in 5 Americans will have
More informationHow To Treat An Elderly Patient
1. Introduction/ Getting to know our Seniors a. Identify common concepts and key terms used when discussing geriatrics b. Distinguish between different venues of senior residence c. Advocate the necessity
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E040 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1.
More informationN-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine (CWM TAF ONLY)
Bro Taf Localities Drugs & Therapeutics Committee SHARED CARE Drugs: Acetylcholinesterase inhibitors - Donepezil, Rivastigmine and Galantamine (Cardiff and Vale and Cwm Taf) Protocol No. CV 52 N-methyl-D-aspartate
More informationManagement in the pre-hospital setting
Management in the pre-hospital setting Inflammation of the joints Two main types: Osteoarthritis - cartilage loss from wear and tear Rheumatoid arthritis - autoimmune disorder Affects all age groups,
More informationMontreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych.
Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych. Community Geriatric Mental Health Model of Continuum of Cognition with Aging Normal Mild cognitive
More informationIs There a Need for New Symptomatic Therapies for Alzheimer s Disease & What Have We Learned from Past Trials of Symptomatic Therapies?
Is There a Need for New Symptomatic Therapies for Alzheimer s Disease & What Have We Learned from Past Trials of Symptomatic Therapies? George T. Grossberg MD Samuel W. Fordyce Professor Department of
More informationTreating patients with compounds or biological agents that pass the safety-test
Treating patients with compounds or biological agents that pass the safety-test There are numerous medical disorders without effective treatments. It is possible that many of un-treatable conditions need
More informationInformation for Prescribing Anti-dementia Drugs. November 2012
Information for Prescribing Anti-dementia Drugs The aim of this document is to provide information about the prescribing of anti-dementia medication for adult patients with dementia following an assessment
More informationBarbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Junior Editor: Karen L.A. Wlock, B.Sc.(Pharm.) - Memantine This edition edited by: B.
Volume 28 (1) 2008 Senior Editor: Contents Barbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. - Dementia Therapy Junior Editor: Karen L.A. Wlock, B.Sc.(Pharm.) - Memantine This edition edited by: B. Cadario
More informationTraumatic brain injury (TBI)
Traumatic brain injury (TBI) A topic in the Alzheimer s Association series on understanding dementia. About dementia Dementia is a condition in which a person has significant difficulty with daily functioning
More informationDEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
More informationDRUG APPROVAL PROCESS FOR THE TREATMENT OF ALZHEIMER S DISEASE
Research DRUG APPROVAL PROCESS FOR THE TREATMENT OF ALZHEIMER S DISEASE There are certain principles that should be followed when involving people with Alzheimer s disease in research. For more information,
More informationBEST in MH clinical question-answering service
Best Evidence Summaries of Topics in Mental Healthcare BEST in MH clinical question-answering service Question In people with moderate (including mild-moderate and moderate-severe) dementia how effective
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2011. All rights reserved.
More informationDEMENTIA AND MILD COGNITIVE IMPAIRMENT John P. Moriarty, MD Week 7
DEMENTIA AND MILD COGNITIVE IMPAIRMENT John P. Moriarty, MD Week 7 Educational Objectives: 1. Define dementia and mild cognitive impairment 2. Understand the appropriate work-up for patients with complaints
More informationTable 1: Approved Memantine Adult Dosage Recommendations 1-6
About Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information
More informationJ/601/2874. This unit must be assessed in accordance with Skills for Care and Development s QCF Assessment Principles.
Unit 13: Dementia Awareness Unit code: DEM 201 Unit reference number: J/601/2874 QCF level: 2 Credit value: 2 Guided learning hours: 17 Unit summary The aim of the unit is to enable learners to gain knowledge
More informationMemantine (Namenda ) [Developed, April 2010; Revised, March 2012; March 2014] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE
Memantine (Namenda ) [Developed, April 2010; Revised, March 2012; March 2014] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE Information on indications for use or diagnosis is assumed to be unavailable.
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationCosts of Medical Care for Dementia Patients in Taiwan: A Population-Based Study
Costs of Medical Care for Dementia Patients in Taiwan: A Population-Based Study L.-J. E. Ku 1, T.-H. Lu 1, S.-L. Wu 1, M.-C. Pai 2* 古 鯉 榕, 呂 宗 學, 吳 士 良, 白 明 奇 April 19, 2013 1 Institute of Public Health,
More informationCurrent Pharmacotherapy for Alzheimer s Disease
Current Pharmacotherapy for Alzheimer s Disease Stephen S. Flitman, MD 1 1 Medical Director, 21 st Century Neurology, a division of Xenoscience Inc., Phoenix, Arizona WORD COUNT: 5449 ABSTRACT This article
More informationStephen L. Benson, Psy.D. November 17, 2015
Stephen L. Benson, Psy.D. November 17, 2015 Biomedical view of dementia Lyman (1989) suggested that the biomedical view of dementia includes three features: First, dementia is pathological and individual,
More informationSubject Review. p.17 Alzheimer s Disease: An Update. p.21 Diabetes Team and Glycemic Control DANIEL A. LLANO, MD, PHD
Subject Review p.17 DANIEL A. LLANO, MD, PHD p.21 Diabetes Team and Glycemic Control MICHAEL JAKOBY, MD, MA, FACP ANN GAREY, NP ROBERT KIRBY, MD KINGSLEY ONYEMERE, MD, MPH JAMES KUMAR, MD RENATO ALCARAZ,
More informationThe Pharmacist s Role in Recognition and Management of Alzheimer s
10:15am - 11:15am: Breakout 2 - Mental Health Option B: The Pharmacist s Role in Recognition and Management of Alzheimer s ACPE UAN 0107-0000-10-013-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based
More informationCopywrite - Eric Freitag, Psy.D., 2012
Diagnosis, Intervention and Care for Patients With Cognitive Impairment Eric J. Freitag, Psy.D, FACPN Diplomate, American College of Professional Neuropsychology Mt. Diablo Memory Center Founder/Executive
More informationAcetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) Version: 3 Date Approved: June 2011 Review
More informationAnti-Parkinsonism Drugs
Anti-Parkinsonism Drugs Pharma Team 429 Fahad Alrumaih Ibrahim Alshiddi Sultan Alsalem Ismail Raslan Suhail Asiri Parkinsonism - Could be: primary [idiopathic] or secondary [viral infection or drug induced
More information1 in 3 seniors dies with Alzheimer s or another dementia.
2013 Alzheimer s disease facts and figures Includes a Special Report on long-distance caregivers 1 in 3 seniors dies with Alzheimer s or another dementia. Out-of-pocket expenses for long-distance caregivers
More informationAlcohol Withdrawal Syndrome & CIWA Assessment
Alcohol Withdrawal Syndrome & CIWA Assessment Alcohol Withdrawal Syndrome is a set of symptoms that can occur when an individual reduces or stops alcoholic consumption after long periods of use. Prolonged
More informationA Support System for Diagnosis of Dementia, Alzheimer or Mild Cognitive Impairment
Toronto, November 4, 2013 04:00 pm 05:30 pm-4th Oral Session A Support System for Diagnosis of Dementia, Alzheimer or Mild Cognitive Impairment Flávio L. Seixas Aura Conci Débora C. Muchaluat Saade Bianca
More informationDementa Formulary Guidance [v1.0]
Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more
More informationDementia: Delivering the Diagnosis
Dementia: Delivering the Diagnosis Daniel D. Christensen, M.D. Clinical Professor of Psychiatry Clinical Professor of Neurology Adjunct Professor of Pharmacology University of Utah Diagnosing Dementia
More informationNeuropsychological Assessment of Early Cognitive Impairment in the Elderly
Neuropsychological Assessment of Early Cognitive Impairment in the Elderly David Loewenstein PhD, ABPP/CN Professor of Psychiatry and Behavioral Sciences Department of Psychiatry, Miller School of Medicine,
More informationGalantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease
IS 17 October 2011 Information sheet Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease Introduction... 1 How does Reminyl work?... 1 Who might benefit?... 2 What effect might Reminyl
More informationTHEORIES OF NEUROLOGICAL AGING AND DEMENTIA
THEORIES OF NEUROLOGICAL AGING AND DEMENTIA Aging Overview The primary care physician must advise middle-age and older patients about ways to age successfully. Dementia is a common disabling illness that
More informationBSc in Medical Sciences with PHARMACOLOGY
BSc in Medical Sciences with PHARMACOLOGY Course Director Dr Christopher John Module Leaders Dr Robert Dickinson (Module 1) Dr Anabel Varela Carver (Module 2) Dr Sohag Saleh (Module 3) Course Administrator
More information9/20/2010. The eye doesn t see what the mind doesn t know. Sir William Osler
The eye doesn t see what the mind doesn t know. Sir William Osler Lewy Body Dementia Atypical Dementia The Lewy Body Spectrum Patricia J. Gifford, MD Silverado Hospice 2009 Progressive loss of intellectual
More informationAlzheimer s Disease 2009. Alzheimer s Disease. Markets, Pipeline and Opportunities. April 2009. By John Bates Ph.D. 1 Copyright 2009 Biopharm Reports
Alzheimer s Disease Markets, Pipeline and Opportunities April 2009 By John Bates Ph.D 1 About the Author John Bates is a consultant and author in the drug markets and R&D fields. After a first degree in
More informationDirecting an Alzheimer s/dementia Care Unit
9135 N. Meridian Street Suite B-4 Indianapolis, IN 46260 (317) 575-9620 (800) 272-3900 September, 2004 Funded by the Indiana State Department of Health Co-sponsored by: Indiana Association of Homes and
More informationSocial Security Disability Insurance and young onset dementia: A guide for employers and employees
Social Security Disability Insurance and young onset dementia: A guide for employers and employees What is Social Security Disability Insurance? Social Security Disability Insurance (SSDI) is a payroll
More informationA Responder Analysis of Memantine Treatment in Patients With Alzheimer Disease Maintained on Donepezil
A Responder Analysis of Memantine Treatment in Patients With Alzheimer Disease Maintained on Donepezil Christopher H. van Dyck, M.D., Frederick A. Schmitt, Ph.D., Jason T. Olin, Ph.D., for the Memantine
More informationBeing an advocate for good care. Useful medications What to expect When to be concerned
Being an advocate for good care Useful medications What to expect When to be concerned Common Medical Questions 1. What medications are available to help with memory loss? Cholinesterase Inhibitors The
More informationCognitive Testing for Underwriting Life Insurance
Cognitive Testing for Underwriting Life Insurance Presentation to the Mortality Working Group of the International Actuarial Association Al Klein April 8, 2011 Cognitive function Agenda What is it? What
More informationAlcohol Overuse and Abuse
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
More informationRecognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
More informationAlzheimer s disease. Information sheet
IS27 September 2003 Information sheet Alzheimer s disease Introduction This information sheet is for people with early Alzheimer s disease who want to know more about their illness, and for carers of people
More information2015 Alzheimer s Disease Facts and Figures
2015 Alzheimer s Disease Facts and Figures Includes a Special Report on Disclosing a Diagnosis of Alzheimer s Disease Alzheimer s Disease is the sixth-leading cause of death in the United States. more
More informationTHE CLINICIAN SHOULD UTILIZE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT.
Acetylcholinesterase Inhibitors* (AChEI) to Treat Dementia: 2015 Update Criteria for Use December 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The
More information2013 Report. New York State Coordinating Council. For Services Related to Alzheimers Disease and. Other Dementias. Governor Andrew M.
2013 Report of the New York State Coordinating Council For Services Related to Alzheimers Disease and Other Dementias to Governor Andrew M. Cuomo and the New York State Legislature Table of Contents Section
More informationhepatolenticular degeneration (E83.0) human immunodeficiency virus [HIV] disease (B20) hypercalcemia (E83.52) hypothyroidism, acquired (E00-E03.
ICD-10-CM Codes for Mental, Behavioral and Neurodevelopmental Disorders Chapter 5 Mental, Behavioral and Neurodevelopmental disorders (F01-F99) Includes: disorders of psychological development Excludes2:
More informationAn Evidence-based Critical Appraisal of a Topic: Effectiveness of High Dose Donepezil for Advanced Alzheimer s Disease
ORIGINAL RESEARCH An Evidence-based Critical Appraisal of a Topic: Effectiveness of High Dose Donepezil for Advanced Alzheimer s Disease Charlene R. Hoffman Snyder, DNP, FNP-BC, and Lynda Facchiano, DNP,
More informationUpdate of Pharmacological Intervention Recommendations for the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012
Update of Pharmacological Intervention Recommendations for the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012 1) New recommendation for the management of Alzheimer s disease
More informationDiagnosis and Initial Management of Cognitive Disorders
Diagnosis and Initial Management of Cognitive Disorders January 29, 2016 Kelly Garrett, PhD Cathleen Obray, MD, MHS Neurosciences Clinical Program Cognitive Care Team None Disclosures Neurosciences Clinical
More informationNo Dementia Stage 2: Very Mild Cognitive Decline
Stages of Dementia Health professionals sometimes discuss dementia in "stages," which refers to how far a person's dementia has progressed. Defining a person's disease stage helps physicians determine
More informationPharmacology of the Central Nervous System (CNS) Dr. Sabry Attia. November 2006
Pharmacology of the Central Nervous System (CNS) Dr. Sabry Attia November 2006 Neurodegenerative disease Neurodegenerative disease is a condition which affects brain function. They are result from deterioration
More information